139 related articles for article (PubMed ID: 11606857)
1. Close correlation of p53 mutation to microvascular invasion in hepatocellular carcinoma.
Park NH; Chung YH; Youn KH; Song BC; Yang SH; Kim JA; Lee HC; Yu E; Lee YS; Lee SG; Kim KW; Suh DJ
J Clin Gastroenterol; 2001; 33(5):397-401. PubMed ID: 11606857
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan.
Hayashi H; Sugio K; Matsumata T; Adachi E; Takenaka K; Sugimachi K
Hepatology; 1995 Dec; 22(6):1702-7. PubMed ID: 7489977
[TBL] [Abstract][Full Text] [Related]
3. Role of p53 and β-catenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma.
Yuan RH; Jeng YM; Hu RH; Lai PL; Lee PH; Cheng CC; Hsu HC
J Gastrointest Surg; 2011 Feb; 15(2):321-9. PubMed ID: 21061181
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness.
Hsu HC; Tseng HJ; Lai PL; Lee PH; Peng SY
Cancer Res; 1993 Oct; 53(19):4691-4. PubMed ID: 8402647
[TBL] [Abstract][Full Text] [Related]
5. Tumor heterogeneity in small hepatocellular carcinoma: analysis of tumor cell proliferation, expression and mutation of p53 AND beta-catenin.
An FQ; Matsuda M; Fujii H; Tang RF; Amemiya H; Dai YM; Matsumoto Y
Int J Cancer; 2001 Aug; 93(4):468-74. PubMed ID: 11477549
[TBL] [Abstract][Full Text] [Related]
6. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas.
Sugo H; Takamori S; Kojima K; Beppu T; Futagawa S
Surg Today; 1999; 29(9):849-55. PubMed ID: 10489124
[TBL] [Abstract][Full Text] [Related]
7. Genetic changes and histopathological grades in human hepatocellular carcinomas.
Konishi M; Kikuchi-Yanoshita R; Tanaka K; Sato C; Tsuruta K; Maeda Y; Koike M; Tanaka S; Nakamura Y; Hattori N
Jpn J Cancer Res; 1993 Aug; 84(8):893-9. PubMed ID: 8407553
[TBL] [Abstract][Full Text] [Related]
8. Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?
Sheen IS; Jeng KS; Wu JY
World J Gastroenterol; 2003 Jun; 9(6):1202-7. PubMed ID: 12800224
[TBL] [Abstract][Full Text] [Related]
9. [The relation between p53 mutations and tumor invasiveness of human hepatocellular carcinoma].
Qin L; Tang Z; Liu K
Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):405-8. PubMed ID: 8697987
[TBL] [Abstract][Full Text] [Related]
10. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation.
Tanaka S; Toh Y; Adachi E; Matsumata T; Mori R; Sugimachi K
Cancer Res; 1993 Jun; 53(12):2884-7. PubMed ID: 8389246
[TBL] [Abstract][Full Text] [Related]
11. p53 gene mutation spectrum in hepatocellular carcinoma.
Oda T; Tsuda H; Scarpa A; Sakamoto M; Hirohashi S
Cancer Res; 1992 Nov; 52(22):6358-64. PubMed ID: 1330291
[TBL] [Abstract][Full Text] [Related]
12. Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection?
Jeng KS; Sheen IS; Chen BF; Wu JY
Arch Surg; 2000 Nov; 135(11):1329-33. PubMed ID: 11074891
[TBL] [Abstract][Full Text] [Related]
13. Tumor-suppressor p53 gene in hepatitis C and B virus-associated human hepatocellular carcinoma.
Shieh YS; Nguyen C; Vocal MV; Chu HW
Int J Cancer; 1993 Jun; 54(4):558-62. PubMed ID: 8390407
[TBL] [Abstract][Full Text] [Related]
14. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection.
Désert R; Rohart F; Canal F; Sicard M; Desille M; Renaud S; Turlin B; Bellaud P; Perret C; Clément B; Lê Cao KA; Musso O
Hepatology; 2017 Nov; 66(5):1502-1518. PubMed ID: 28498607
[TBL] [Abstract][Full Text] [Related]
15. Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma.
Tamori A; Nishiguchi S; Nishikawa M; Kubo S; Koh N; Hirohashi K; Shiomi S; Inoue M
J Gastroenterol; 2004 Nov; 39(11):1063-8. PubMed ID: 15580399
[TBL] [Abstract][Full Text] [Related]
16. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
17. p53 mutation is a poor prognostic indicator for survival in patients with hepatocellular carcinoma undergoing surgical tumour ablation.
Honda K; Sbisà E; Tullo A; Papeo PA; Saccone C; Poole S; Pignatelli M; Mitry RR; Ding S; Isla A; Davies A; Habib NA
Br J Cancer; 1998 Mar; 77(5):776-82. PubMed ID: 9514057
[TBL] [Abstract][Full Text] [Related]
18. [Expression of phosphatase and tensin homology deleted on chromosome ten(PTEN) and p53 protein and their significance in human hepatocellular carcinomas].
Cheng LM; Wang SY; Lin JS
Ai Zheng; 2003 Jan; 22(1):42-5. PubMed ID: 12561434
[TBL] [Abstract][Full Text] [Related]
19. Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes.
Yano M; Hamatani K; Eguchi H; Hirai Y; MacPhee DG; Sugino K; Dohi K; Itamoto T; Asahara T
Eur J Cancer; 2007 Apr; 43(6):1092-100. PubMed ID: 17350822
[TBL] [Abstract][Full Text] [Related]
20. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma.
Peng SY; Chou SP; Hsu HC
J Hepatol; 1998 Aug; 29(2):281-9. PubMed ID: 9722210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
